<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02548650</url>
  </required_header>
  <id_info>
    <org_study_id>IIS 53377</org_study_id>
    <nct_id>NCT02548650</nct_id>
  </id_info>
  <brief_title>Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus</brief_title>
  <acronym>OPTIMUS-5</acronym>
  <official_title>Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently
      clopidogrel, represents the standard of care for the long-term secondary prevention of
      atherothrombotic events in patients with myocardial infarction (MI) or peripheral arterial
      disease (PAD). However, rates of ischemic recurrences remain high. Vorapaxar is a
      protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of
      thrombin-mediated platelet aggregation. Patients with diabetes mellitus (DM) are known to be
      at increased risk of recurrent atherothrombotic events, which translates into worse outcomes,
      despite the use of standard of care therapy. This is in part due to the hyperreactive
      platelet phenotype, which characterizes DM patients, and to inadequate response to oral
      antiplatelet agents, including clopidogrel. Therefore, vorapaxar is an attractive treatment
      option for DM patients with a prior MI. The pharmacodynamic (PD) effects of vorapaxar in DM
      patients and how these may differentiate from non-DM patients has not been explored. Further,
      the role of vorapaxar as part of a dual antithrombotic treatment regimen combined with
      clopidogrel (and stopping aspirin) represents another important area of clinical interest.
      The proposed prospective, parallel-design study conducted in patients post-MI or with PAD
      with and without DM will aim the assess the pharmacodynamic effects of vorapaxar in addition
      to standard DAPT with aspirin and clopidogrel as well as in combination with clopidogrel only
      following aspirin withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently
      clopidogrel, represents the standard of care for the long-term secondary prevention of
      atherothrombotic events in patients with myocardial infarction (MI) or peripheral arterial
      disease (PAD). However, rates of ischemic recurrences remain high, in part due to the fact
      that other platelet signaling pathways, such as thrombin-induced platelet aggregation,
      continue to be activated. Vorapaxar is a novel, orally active, competitive and slowly
      reversible protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of
      thrombin-mediated platelet aggregation. It is approved for clinical use by the Food and Drug
      Administration for the reduction of thrombotic cardiovascular events in patients with a
      history of MI or with peripheral arterial disease. Patients with DM are known to be at
      increased risk of recurrent atherothrombotic events, which translates into worse outcomes,
      despite the use of standard of care therapy. This is in part due to the hyperreactive
      platelet phenotype, which characterizes DM patients, and to inadequate response to oral
      antiplatelet agents, including clopidogrel. Importantly, in DM patients with prior MI
      included in the TRA 2P trial, vorapaxar reduced the primary composite end point at 3 years by
      27% and led to a greater absolute risk reduction compared with those without DM. Therefore,
      vorapaxar is an attractive treatment option for DM patients with a prior MI. However, to date
      the PD effects of vorapaxar in DM patients and how these may differentiate from non-DM
      patients has not been explored. Further, current trends in clinical practice are seeing many
      patients discontinue aspirin and maintain clopidogrel. Hence, the role of vorapaxar as part
      of a dual antithrombotic treatment regimen combined with clopidogrel (and stopping aspirin)
      represents another important area of clinical interest, in order to maximize ischemic
      protection while reducing the risk of bleeding. The proposed prospective, parallel-design
      study conducted in patients post-MI or with PAD with and without DM will aim the assess the
      pharmacodynamic effects of vorapaxar in addition to standard DAPT with aspirin and
      clopidogrel as well as in combination with clopidogrel only following aspirin withdrawal.
      Pharmacodynamic assessments will be performed at multiple time point, with different assays
      exploring multiple pathways of platelet aggregation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal platelet aggregation</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between vorapaxar plus DAPT and vorapaxar plus clopidogrel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal platelet aggregation achieved with vorapaxar plus DAPT</measure>
    <time_frame>30 days</time_frame>
    <description>Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between diabetic and non diabetic patients treated with vorapaxar plus DAPT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Patients with diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorapaxar</intervention_name>
    <description>Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days</description>
    <arm_group_label>Patients with diabetes</arm_group_label>
    <arm_group_label>Patients without diabetes</arm_group_label>
    <other_name>Zontivity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days</description>
    <arm_group_label>Patients with diabetes</arm_group_label>
    <arm_group_label>Patients without diabetes</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days</description>
    <arm_group_label>Patients with diabetes</arm_group_label>
    <arm_group_label>Patients without diabetes</arm_group_label>
    <other_name>ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with a prior MI between 2 weeks and 24 months or with PAD.

          2. On DAPT with low-dose aspirin (81mg od) and clopidogrel (75mg od) as per
             standard-of-care for at least 14 days.

          3. Age â‰¥ 18 years old.

        Exclusion criteria:

          1. History of acute coronary syndrome in the previous 2 weeks.

          2. History of stroke, transient ischemic attack, or intracranial hemorrhage.

          3. Active pathological bleeding, history of bleeding events or increased risk of
             bleeding.

          4. Known severe hepatic impairment.

          5. Use of strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole, itraconazole,
             posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir,
             indinavir, boceprevir, telaprevir, telithromycin and conivaptan) or inducers (e.g.,
             rifampin, carbamazepine, St. John's Wort and phenytoin).

          6. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran,
             rivaroxaban, apixaban, edoxaban).

          7. On treatment with any antiplatelet agent other than aspirin and clopidogrel in the
             past 14 days.

          8. Creatinine clearance &lt;30 mL/minute.

          9. Platelet count &lt;80x106/mL

         10. Hemoglobin &lt;10g/dL

         11. Hemodynamic instability

         12. Pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick J Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida College of Medicine-Jacksonville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominick J Angiolillo, MD, PhD</last_name>
    <phone>+1-904-244-3378</phone>
    <email>dominick.angiolillo@jax.ufl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominick J Angiolillo, MD, PhD</last_name>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Dominick J Angiolillo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>vorapaxar</keyword>
  <keyword>peripheral arterial disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Vorapaxar</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

